Physician profile
Daniela K Spitzer
NPI 1184738510
$5,461.46
in general payments reported to CMS, 2019-2025
36 companies · $298 in 2025
The $298 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,148 · 2020: $828 · 2021: $1,809 · 2022: $286 · 2023: $72.05 · 2024: $20.31 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $390.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $864.03 | 2019-2023 | Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $504.43 | 2019-2021 | |
| Novo Nordisk INC | $453.78 | 2019-2021 | |
| Allergan, INC. | $361.97 | 2019-2020 | |
| Cumberland Pharmaceuticals, INC. | $347.10 | 2019-2021 | |
| Amarin Pharma, INC. | $326.10 | 2019-2021 | |
| Lilly USA, LLC | $288.76 | 2019-2024 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $199.63 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $184.82 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $180.11 | 2019-2021 | |
| Pfizer INC. | $178.11 | 2019-2023 | |
| Heartflow, INC. | $155.46 | 2025 | |
| Novartis Pharmaceuticals Corporation | $151.35 | 2019-2020 | |
| Medtronic, INC. | $142.65 | 2025 | O-Arm |
| Optinose US, INC. | $119.93 | 2020-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $114.53 | 2022 | |
| Glaxosmithkline, LLC. | $109.16 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $102.61 | 2022 | |
| Janssen Pharmaceuticals, INC | $99.48 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $95.10 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $83.30 | 2019 | |
| Eisai INC. | $66.75 | 2020-2021 | |
| Abbott Laboratories | $53.57 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $39.98 | 2019 | |
| Genentech USA, INC. | $39.58 | 2019-2021 | |
| Astellas Pharma US INC | $33.45 | 2019 | |
| Currax Pharmaceuticals LLC | $26.97 | 2021 | |
| Daiichi Sankyo INC. | $26.13 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.72 | 2019 | |
| Ironwood Pharmaceuticals, INC | $16.31 | 2019 | |
| Paratek Pharmaceuticals, INC. | $15.93 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.11 | 2019 | |
| Sanofi Pasteur INC. | $12.38 | 2019 | |
| Ibsa Pharma INC. | $11.96 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.14 | 2021 | |
| Esperion Therapeutics, INC. | $11.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Spitzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.